Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, Pandit-Abid N, Laws E, Akinlade B, Mannent LP, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Papi A, et al. Among authors: gall r. Respir Med. 2024 Apr;224:107535. doi: 10.1016/j.rmed.2024.107535. Epub 2024 Jan 23. Respir Med. 2024. PMID: 38272376 Free article.
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, Hardin M. Sher LD, et al. Among authors: gall r. Chest. 2022 Jul;162(1):46-55. doi: 10.1016/j.chest.2022.01.071. Epub 2022 Feb 22. Chest. 2022. PMID: 35217003 Free article. Clinical Trial.
Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation.
Hanania NA, Maspero JF, Halpin DMG, Jackson DJ, Panettieri RA, Castro M, Domingo C, Daizadeh N, Gall R, Jacob-Nara JA, Ortiz B, Djandji M, Rowe PJ, Deniz Y. Hanania NA, et al. Among authors: gall r. J Asthma Allergy. 2022 Jun 28;15:851-854. doi: 10.2147/JAA.S354013. eCollection 2022. J Asthma Allergy. 2022. PMID: 35789920 Free PMC article. No abstract available.
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.
Maspero JF, Cardona G, Schonffeldt P, Tolcachier A, González-Diaz SN, Yañez A, Galvao CE, Msihid J, Gall R, Siddiqui S, Rowe PJ, Deniz Y, Jacob-Nara JA, Djandji M. Maspero JF, et al. Among authors: gall r. J Asthma. 2023 May;60(5):981-990. doi: 10.1080/02770903.2022.2115927. Epub 2022 Oct 17. J Asthma. 2023. PMID: 36066123 Clinical Trial.
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
Brusselle G, Quirce S, Papi A, Kuna P, Chipps BE, Hanania NA, Blaiss M, Msihid J, Jacob-Nara JA, Deniz Y, Rowe PJ, Gall R, Ortiz B, Djandji M, Radwan A. Brusselle G, et al. Among authors: gall r. J Allergy Clin Immunol Pract. 2023 Mar;11(3):873-884.e11. doi: 10.1016/j.jaip.2022.11.044. Epub 2022 Dec 23. J Allergy Clin Immunol Pract. 2023. PMID: 36572184 Free article.
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma.
Jackson DJ, Bacharier LB, Phipatanakul W, Sher L, Domingo C, Papadopoulos N, Modena B, Li N, Xia C, Kamal MA, Dillon M, Wolfe K, Gall R, Amin N, Mannent LP, Laws E, Rowe PJ, Jacob-Nara JA, Deniz Y, Lederer DJ, Hardin M, Xu C. Jackson DJ, et al. Among authors: gall r. Ann Allergy Asthma Immunol. 2023 Jul;131(1):44-51.e4. doi: 10.1016/j.anai.2023.03.014. Epub 2023 Mar 22. Ann Allergy Asthma Immunol. 2023. PMID: 36958470 Free article. Clinical Trial.
104 results